Earnings call
Sun Pharmaceutical Industries Q3 FY26 earnings call: Sun Pharmaceutical Industries Limited's current phase-2b study is expected to possibly finish within 12-to-18 months
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
Current phase-2b study is expected to possibly finish within 12-to-18 months. The company received a milestone payment of US$45 million in the corresponding quarter of FY '25. Sun Pharma is ranked No. 1 and holds 8.4% market share in the over Rs. 2,407 million Indian pharmaceuticals market as per Pharmarack MAT December 2025. The company had net cash of $3.2 billion at the consolidated level.
The numbers management gave
Results
- The company received a milestone payment of US$45 million in the corresponding quarter of FY '25.
Show source
In the corresponding quarter of FY '25, Sun had received a milestone payment of US$45 million.
- Gross margin was 81% in the 3rd Quarter of FY 2026, higher than the same period last year largely on account of better product mix.
Show source
Gross margin during the quarter was at 81%, higher than the same period last year, largely on account of better product mix.
- EBITDA was Rs.49,485 million in the 3rd Quarter of FY 2026, up 23.4% over Q3 last year, and EBITDA margin was 31.9%, higher year-on-year and quarter-on-quarter.
Show source
EBITDA for the quarter was Rs.49,485 million, an increase of 23.4% over Q3 last year.
- The company took an exceptional charge of Rs.4,895 million in the 3rd Quarter of FY 2026, primarily on account of wage code gratuity as per ICI guidelines and an additional provision for GxMDL final settlement.
Show source
During the quarter, an exceptional charge of Rs.4,895 million was taken primarily on account of wage code gratuity as per ICI guidelines and additional provision for GxMDL final settlement.
- Reported net profit after tax was Rs.33,688 million in Q3 FY2026, up 16% over Q3 last year.
Show source
Reported net profit after tax for Q3 FY2026 was Rs.33,688 million, up by 16% over Q3 last year.
- Adjusted net profit was Rs.35,367 million in the 3rd Quarter of FY 2026, up 9.9%.
Show source
Adjusted net profit for the quarter was Rs.35,367 million, up 9.9%.
Show 17 more statements
Results
- EPS was Rs.14 per share in the 3rd Quarter of FY 2026.
Show source
EPS for the quarter was Rs.14 per share.
- Effective tax rate was 24.3% in the 3rd Quarter of FY 2026, compared with 14.7% in the 3rd Quarter of FY25 and 24.7% in Q2 FY26.
Show source
Effective tax rate for the quarter was 24.3%, vis-à-vis 14.7% in 3rd Quarter of FY25 and 24.7% in Q2 FY26.
- The company recorded a FOREX gain of Rs.1,539 million in the 3rd Quarter of FY 2026.
Show source
FOREX gain during the quarter was Rs.1,539 million.
- Gross margin was 80% for the first nine months of FY26.
Show source
Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Gross margin was at 80% for the first nine months.
- EBITDA was Rs.1,37,772 million for the first nine months of FY26, up 19.2%, with an EBITDA margin of 31.4%.
Show source
EBITDA came in at Rs.1,37,772 million, registering a growth of 19.2% with a resulting EBITDA margin of 31.4%.
- India formulations sales were Rs.49,986 million in Q3, up 16.2% over Q3 last year, and accounted for 32.3% of total consolidated sales for the quarter.
Show source
Coming to India business: For Q3 sales formulations in India were Rs.49,986 million, recording a growth of 16.2% over Q3 last year.
- Overall US business was $477 million in the 3rd Quarter of FY 2026, up 0.6%; growth in innovative medicines was offset by lower generic sales due to additional competition in certain products.
Show source
Let me share the performance highlights of our US Business: Our overall US business was marginally up by 0.6% to reach $477 million for the quarter.
- US business accounted for 27.5% of consolidated sales in the 3rd Quarter of FY 2026.
Show source
The US accounted for 27.5% of consolidated sales for the quarter.
- Emerging markets accounted for 19.4% of Sun Pharmaceutical Industries Limited's total consolidated revenue in Q3.
Show source
Emerging markets accounted for 19.4 % of total consolidated revenue for Q3.
- Formulations revenues in the rest of the world were US $296 million in Q3, up 14.5% over Q3 FY25.
Show source
Formulations revenues in the rest of the world were US $296 million, up 14.5 % over Q3 FY25.
- The rest of the world markets accounted for approximately 17.1% of Sun Pharmaceutical Industries Limited's consolidated revenue.
Show source
The rest of the world markets accounted for approximately 17.1 % of consolidated revenue.
- Consolidated R&D investments were Rs.8,928 million, or 5.8% of sales, in Q3 FY26.
Show source
Consolidated investments made towards R&D for Q3 FY26 stand at Rs.8,928 million or 5.8% of sales.
- Innovative R&D accounted for 30.5% of Sun Pharmaceutical Industries Limited's total R&D spend and was 7.2% of global innovative medicines sales in the 3rd Quarter of FY 2026.
Show source
Innovative R&D accounted for 30.5% of our total R&D spend and stands at 7.2% of global innovative medicines sales for the quarter.
- Effective tax rate moved from around 13% to 15% to currently about 25%, which management said is why PAT improvement may not be commensurate with margin improvement.
Show source
Our ETR has moved up from around 13 % to 15% to currently about 25% and that is the reason why you would see that the PAT improvement may not be commensurate with the margin improvement.
- Emerging markets business had constant currency growth of 13% in the 3rd Quarter of FY 2026; both generics and innovative businesses did well despite a currency tailwind.
Show source
And our constant currency growth for the emerging markets business is 13%.
- EBITDA margins improved mostly on account of better product mix, excluding the impact of milestone income, favorable FOREX impact and other operating revenues.
Show source
Excluding the impact of milestone income, favorable FOREX impact and other operating revenues, EBITDA margins for the company improved mostly on account of better product mix.
Money and capital
- The company had net cash of $3.2 billion at the consolidated level.
Show source
Balance sheet continues to be strong with a net cash of $3.2 billion at the consolidated level.
What it expects ahead
What management expects
- Current phase-2b study is expected to possibly finish within 12-to-18 months.
Show source
But the current phase-2b study which has started, that should possibly get over within maybe 12-to-18 months.
- The company will launch three new generic products in the US in Q3.
Show source
Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 In Q3, we will launch three new generic products in the US.
- Spend on the LEQSELVI and UNLOXCYT launches was fairly evenly split, and spend was increasing in the latter part of the fiscal year, particularly following the UNLOXCYT launch; the company expects this spend to be part of core expenses going forward.
Show source
So, the spend is really occurring on the LEQSELVI, UNLOXCYT launches, was fairly evenly split.
- The company expects launch support for these products and the rest of its innovative medicines business to be part of core operating OPEX next year. Replaced by a later filing.
Show source
Richard Ashcroft: Yes, next year it will just be part of our core operating OPEX to support these and the rest of our innovative medicines business.
What it is building and selling
Demand and pricing
- Sun Pharma is ranked No. 1 and holds 8.4% market share in the over Rs. 2,407 million Indian pharmaceuticals market as per Pharmarack MAT December 2025.
Show source
Sun Pharma is ranked No. 1 and holds 8.4% market share in over Rs. 2,407 million Indian pharmaceuticals market as per Pharmarack MAT December 2025.
- US generics business, excluding Lenalidomide, was slightly down due to specific competition for certain products.
Show source
Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Richard Ashcroft: It is really due to specific competition for certain products.
Segments
- The company launched Unloxcyt in the US for the treatment of Advanced Cutaneous Squamous Cell Carcinoma.
Show source
As Kirti mentioned, recently we have also launched Unloxcyt in the US for the treatment of Advanced Cutaneous Squamous Cell Carcinoma.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Rishi Parekh: Hi, good morning and good evening, I guess, and thank you so much for taking my question. Now, I appreciate you are not taking questions on what is speculative out there, but for many of us that are new to Sun Pharma, I was just hoping that you could walk us through your M&A strategy and what you are hoping to target or achieve with the strategy. Are you looking at tuck-ins, are you looking to add biosimilars, are you looking to expand your geographic presence, and how important is North America in the strategy?
Answer, dilip shanghvi
Dilip Shanghvi: So, I think almost for all of those issues, we have indicated responses to the analysts on this call in the past. I think US continues to be an important part of our focus, specifically for the innovative medicines… and not only US, but we have interest in selling innovative medicines globally. For emerging markets, we are looking at what you call tuck -ins or smaller acquisitions, which we can look at integrating with our existing business to get scale in the emerging markets. And we have also consistently indicated that we want to remain disciplined about acquisition. Our focus is on finding a way to grow our business organically at a rate so that we continue to be an attractive investment opportunity for the shareholders. We would look at acquisition only if we think that it can help us in terms of strengthening our long -term strategy capability.
Question
Rishi Parekh: And then can you also talk us through the size of the types of acquisitions you are looking at? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Dilip Shanghvi: So, I think we have indicated in the past that we need to be confident that whatever acquisition we make, we should be able to manage effectively without our diluting focus on our own growth.
Answer, dilip shanghvi
At the same point of time, I think we have also indicated that for acquisition, if it is necessary, we are comfortable in raising debt.
Question
Tushar Manudhane: Thanks for the opportunity. Sir, on the innovative medicines sales, ex of milestone payment, the growth has been a bit soft compared to the earlier quarters. If you could elaborate on that? That is my first question.
Answer, kirti ganorkar
Kirti Ganorkar: Yes, I will answer your question. As we have called out in our Q3 FY2 5, certain one-time sales to our partner and that has given Q3 FY25 high base and that is one reason for the growth looking lower in H1. However, specialty should continue to do well. It is difficult for us to comment quarter -to-quarter. My view is always you look at the business on annualized basis rather than looking at quarter-to-quarter basis.
Question
Tushar Manudhane: Secondly, R&D spend on the innovative portfolio both as a percentage of total R&D as well as absolute amount has been reducing for the past two, three quarters. If you could also explain that?
Answer, dilip shanghvi
Dilip Shanghvi: I think it is all linked with commencing clinical trials as we are commencing new clinical trial including the one for GL34. We should increase in the R&D spend and next quarter we will guide R&D next year. That will be our expected R&D spend for next year.
Question
Tushar Manudhane: Yes.
Answer, richard ashcroft
Richard Ashcroft: Ex-Lenalidomide, the generics business is slightly down in the US. Tushar Manudhane: So, is this to do with price erosion or the lack of launches, if you could also explain that? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Richard Ashcroft: It is really due to specific competition for certain products.
Question
Tushar Manudhane: So how do you see this improving going forward?
Answer, richard ashcroft
Richard Ashcroft: I think overall for the US, we see the innovative medicines continuing to grow and the generic business will start to recover once we are in manufacturing compliance for a number of our sites in order to launch new products.
Question
Damayanti Kerai: Hi, good evening and thank you for the opportunity. My first question is on gross margins. I just want to understand it better. In your opening remarks you mentioned better mix led to such strong gross margins. So, if you could just explain what are the key drivers to sustain such high gross margins? As we understand now Re vlimid benefit is over for you. So if some additional color to explain the very strong growth margin performance ?
Answer, jayashree satagopan
Jayashree Satagopan: Thanks for your question , Damayanti. As you know , we do not specifically guide on product margins. Having said that better mix of products both in terms of the branded products and our innovative medicines has given an upt ick compared to the gross margin in the previous year.
Question
Damayanti Kerai: Okay. You think this level of margins will sustain or how do you see margins trending ahead?
Answer, jayashree satagopan
Jayashree Satagopan: As I was just mentioning , we normally do not guide on margins. Our endeavor is to see how we sustain and really perform to our potential.
Question
Damayanti Kerai: Okay, sure. My second question is on spend on the new launches where you indicated incremental spend of 100 million or so. So , in terms of spend how much of that is already covered and how much is yet to come and where are the major spend happening?
Answer, richard ashcroft
Richard Ashcroft: I am happy to address that. So, the spend is really occurring on the LEQSELVI, UNLOXCYT launches, was fairly evenly split. We do see that spend is increasing now in the latter part of the fiscal year particularly as we have just launched UNLOXCYT. We do expect this to be kind of part of our core expenses though going forward. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Damayanti Kerai: Okay.
Question
So next year as well we expect elevated spend on these new launches as you build up the markets, etc.?
Answer, richard ashcroft
Richard Ashcroft: Yes, next year it will just be part of our core operating OPEX to support these and the rest of our innovative medicines business.
Show 21 more questions
Question
Damayanti Kerai: Yes.
Answer, richard ashcroft
Richard Ashcroft: Sure. So, we are having active discussions with the physicians as you would expect given we are just a few weeks outside of launch. From a distribution perspective, the distribution network is in place. As I had shared, those agreements are in place , the product has been stocked as well as the agreements with the downstream customers. The other important discussions are with health systems. As this is an oncology product, a lot of the prescriptions will come from health systems. So , we have been in active discussions with health systems since before launch.
Answer, richard ashcroft
We have been in touch with the top 50 cancer centers within the U.S., and all of those discussions have been progressing positively. So , for the first few weeks, very pleased with what we have seen so far. The message is resonating in terms of the balance that this product provides in terms of efficacy and safety. It is something that the clinicians have been looking for. And again, within the health systems, the discussions from a formulary perspective have been progressing positively.
Question
Neha Manpuria: Yes, thanks for taking my question. My first question is on the India business. Given the strong performance that we have seen and the upcoming launch of SEMA that you indicated, should we expect this growth rate to improve further as we look through the next few quarters, particularly as we add SEMA? And just a related question on that, would we need to add any more sales force or any plans to expand the sales force in India generally for SEMA or otherwise given the strong growth that we have seen? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free
Answer, kirti ganorkar
So , we will not comment on that. Coming to your question on GLP -1, yes, we will add some few field force for the launch of the product. And that is like the way we do the business in India.
Question
Neha Manpuria: And this has not been done as yet, sir?
Answer, kirti ganorkar
Kirti Ganorkar: Yes, we are preparing for the launch, as I said in my readout. So , some of this thing has already been done, yes.
Question
Neha Manpuria: Understood. And on biosimilars, has your view there changed in terms of looking at that opportunity overall?
Answer, dilip shanghvi
Dilip Shanghvi: I think last time also I indicated . So, we are evaluating, re -looking at, because we look at comprehensively including setting up manufacturing , investment, overall cost of development and the time for the investment to produce any kind of meaningful return. So , we are evaluating everything to take a decision.
Question
Neha Manpuria: Understood. And sorry, if I may squeeze one last question on UNLOXCYT. How are we thinking about positioning this product versus at the end, would it be the warehousing patients that we would look at first or the new patients that are coming? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Richard Ashcroft: I think the position of UNLOXCYT in the market
Answer, richard ashcroft
What it really offers is balance between efficacy and tolerability. So UNLOXCYT works three ways. It restores adaptive immunity, which is by binding to the PD-L1. It engages the innate immune system based on its active FC domain that activates natural killer cells. And unlike the existing product, it preserves PD-L2 signaling. And the reason that is important is that is the pathway through which immune-mediated adverse events are typically anticipated. So that is really the positioning of UNLOXCYT in the marketplace.
Answer, richard ashcroft
And as I said, that has been resonating with, with clinicians.
Question
Neha Manpuria: And do you think this would be more important in getting new patients onboard or could we initially go after the patients that have used existing products and work for them?
Answer, richard ashcroft
Richard Ashcroft: We would mostly anticipate new patients.
Question
Bino Pathiparampil: Got it. Second, on Semaglutide, are you also planning for launches in some other emerging markets around the time you will launch in India?
Answer, kirti ganorkar
Kirti Ganorkar: No, what I said about the launch in India only, other markets we are not guiding what is our launch plan.
Question
Bino Pathiparampil: GL0034 in diabetes Phase-II. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Dilip Shanghvi: We are publishing phase-2a data in the certain scientific conferences, both for diabetes as well as for NASH over the next few months.
Answer, dilip shanghvi
But the current phase-2b study which has started, that should possibly get over within maybe 12-to-18 months.
Question
Girish Bakhru: Yes, thanks for taking my question. Just the questions on US again regarding the two products, first LEQSELVI. My understanding is the product requires a genetic testing before you put the patient on. Can you talk about that? Is not that a significant deterrent?
Answer, richard ashcroft
Richard Ashcroft: Yes. Well, first, I think it is important to point out for all the JAK inhibitors, there is a whole battery of testing that needs to take place. So that is similar across all the products. LEQSELVI is a bit unique in that we do have a specific testing for how the drug is metabolized. What is interesting about that is a lot of drugs are metabolized through that system. So, it is good for patients to understand that. So, there is some benefits of knowing that as part of the testing process.
Answer, richard ashcroft
But you are correct. That is one of the steps associated with starting patients on LEQSELVI.
Answer, richard ashcroft
Richard Ashcroft: We are actually covering the cost of the test. So, we are working with the leading providers. There are several big providers of testing within the United States, and we are working with them to provide the test, and we do so free of charge to the patient.
Question
Girish Bakhru: Understood. And just while we are on this market, I mean, RINVOQ, of course, is being talked about as a new entrant potentially soon. I mean, I was looking at the data. Data of RI NVOQ is pretty solid. And its dosing is also better than LEQSELVI. So how do you see that competition coming in this market? And of course, there are a whole set of new drugs also probably being targeted in Alopecia. Richard Ashcroft: I do not know if I would agree with the comment about the dosing being better. I think what I would say is, first of all, this remains a category where there is opportunity for more diagnosis. So the more products that are available is a good thing because it is getting
Answer, leqselvi bakhru
Girish Bakhru: Understood. And second question was on UNLOXCYT. I heard your comment earlier that this primary market is basically new patients. So, I mean, you are not really targeting patients who have failed Keytruda or Libtayo, is that correct?
Answer, richard ashcroft
Richard Ashcroft: Well, there could be patients that are having trouble tolerating Keytruda and Liptayo that could move to UNLOXCYT. But in general, our assumption has been and our strategy has been more focused on new patients.
Question
Girish Bakhru: But would not that market be smaller like given the advanced carcinoma patients would be difficult to find?
Answer, richard ashcroft
Richard Ashcroft: Yes. I mean, it is smaller than the overall population, but there is a meaningful population of patients that start immunotherapy where they need to go on one of these therapies.
Question
Girish Bakhru: Understood. And lastly, any thoughts on new indications that you are pursuing for LEQSELVI or UNLOXCYT right now or is it too early?
Answer, richard ashcroft
Richard Ashcroft: We are in active discussions about LCM for both the products.
Question
Vishal Manchanda: Hi, good evening and thanks for the opportunity. A question on your pending ANDAs and NDAs. So, you have 116 ANDAs pending and about 14 NDAs pending approval. Would you be able to share how many of these are from sites that are impacted by OAI?
Answer, alok shanghvi
Alok Shanghvi: So, we do not specifically disclose which AND As are filed from which site. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Vishal Manchanda: In the sense, like just a percentage of the spending ANDAs or NDAs that would be filed from the affected sites?
Answer, alok shanghvi
Alok Shanghvi: Like I said, we do not disclose that.
Question
Vishal Manchanda: Okay. And just one final one. Do you expect to see further decline in US generic sales in Q4?
Answer, dilip shanghvi
Dilip Shanghvi: I mean, it is included in our overall guidance.
Question
Vishal Manchanda: Right. And if you could just share between UNLOXCYT and LEQSELVI, which one would scale up faster over the next two years , any sense there?
Answer, richard ashcroft
Richard Ashcroft: We typically do not provide product-specific guidance.
Question
Kunal Dhamesha: Hi, thank you for taking my question. The first one is on the CMS's proposal on the most favored nation pricing, the two models that they have put out. Can you share some color , What is the internal assessment? I believe right now it is open for the commentary.
Answer, richard ashcroft
Richard Ashcroft: Sure. Happy to do so. I think, as you know, there are three models. There is a voluntary model that exists today, which is called the generous model, which is directly related to Medicaid within the US, and then the other two are proposed. So they are very much in the notice and comment phase. We expect that notice and comment phase to end within this next month. So, it is pretty speculative at this point to know, whether they will stay intact as they are or how they will change.
Answer, richard ashcroft
As you would expect, we are working on all possible alternatives to mitigate any impact. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Kunal Dhamesha: Can you share how we can make the broader aspect as to how we can mitigate, what are the strategies we can employ there?
Answer, dilip shanghvi
Dilip Shanghvi: I think these are commercially sensitive information. It is difficult for us to share this information on a public call. If you see, none of the pharma companies have given any details about any agreement that they have signed with the government excepting which products are covered. So, I think you need to understand that there are things that we can share, and there are things that we will not be able to share.
Question
Kunal Dhamesha: Sure, sir. Second one on the Cosibelimab, we just suggested that we might be in active discussion for a new indication. So, would this indication be within the therapy areas that we are focusing or we are willing to go beyond our key therapy areas at this moment given the data especially on the immune-mediated adverse events is quite strong compared to the competitors?
Answer, dilip shanghvi
Dilip Shanghvi: So, I think once we decide, we will share both the information that we can share. As we have said, we are evaluating. So, while we evaluate, there are advantages of staying within the therapy area that we are present in. There are advantages of looking at the other areas that we are not present in. So, we have to do a commercial risk-benefit and time-to-market analysis.
Question
Kunal Dhamesha: Sure. Thank you and all the best.
Answer, kirti ganorkar
Kirti Ganorkar: I think I talked about launch in India, but we will not comment specifically on capacity and whether it is in-house or it is outsourced from a third-party. Gautam: All right. And you guys do not have any timelines or any intention outside India market, any emerging markets, or only India market will be added as of now?
Answer, kirti ganorkar
Kirti Ganorkar: As I said earlier, my comment was only on India market. Outside India market, we are not going to disclose what is our plan here. Gautam: All right. Thank you. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 Moderator: Next question is from Tushar Manudhane from Motilal Osw al Financial Services.
Question
Tushar Manudhane: Ma'am, I was referring about the growth in EBITDA as well as PAT . While higher spend on innovative medicine s to some extent got offset with lower R&D spend compared to earlier years, right?
Answer, jayashree satagopan
Jayashree Satagopan: Yes. So, that is at EBITDA level. PAT , we have indicated in the past as well. Our ETR has moved up from around 13 % to 15% to currently about 25% and that is the reason why you would see that the PAT improvement may not be commensurate with the margin improvement.
Question
Tushar Manudhane: Okay. Subsequently, is 25% expected to be a number to assume for the '27-28?
Answer, jayashree satagopan
Jayashree Satagopan: I think it would be sort of in the range we guess.
Question
Foram Parekh: Thank you for the opportunity. Our emerging markets growth is quite buoyant in this quarter. So, I hear that it was led by both generics as well as innovative products. But can we elaborate more on this and give us some direction, like going forward how should we look at this region?
Answer, alok shanghvi
Alok Shanghvi: So, all our major geographies in emerging markets are doing well in local currency terms. And our constant currency growth for the emerging markets business is 13%. While there was a currency tailwind, Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY26 Earnings Call Transcript 06:30 pm Jan 31, 2026 both generics and innovative businesses have done well, and we do not guide on revenue growth for specific businesses.
Questions about this call
- When was the Sun Pharmaceutical Industries Q3 FY26 earnings call transcript filed?
- Sun Pharmaceutical Industries filed the transcript with the exchange on 4 Feb 2026. This page is built from that transcript.
- What does this page list?
- 30 statements from the transcript across 5 topics, 24 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 31 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.